Getting on the Bandwagon of Innovative Point-of-Care Diagnostic Devices to Boost Primary Healthcare in India: A Short Critique and Way Forward

Arvind Vashishta Rinkoo*, Anand Kumar Panjijyar, Arnika Sharma, Dinesh Songara, Rajesh Ranjan Singh, Dipanjan Sujit Roy, Rakesh Kumar Srivastava

The Wadhwani Initiative for Sustainable Healthcare (WISH), New Delhi, India

ABSTRACT

This short critique aims to share the evolving regulatory environment and compliance challenges that innovators, nanotechnologists, and public health enthusiasts in India ought to keep in mind before hopping on the bandwagon of innovative point-of-care diagnostic devices in the primary healthcare space. More significantly, the priority-setting approach suggested by the authors needs to be adapted through iterative practice and refinement in order to identify innovative point-of-care diagnostic devices that can eventually raise the quality and cost-effectiveness of healthcare provisions at the last-mile.

Keywords: Innovation; Primary healthcare; Point-of-care; Medical devices; India

BACKGROUND

In October 2018, 197 countries around the world ratified the Declaration of Astana. The Astana declaration reminded the developing countries of the significance of robust primary healthcare as a strong foundation of any health system and as the cornerstone for attaining universal health coverage. If health-related sustainable development goals (SDG) are to be achieved, developing countries such as India need to ensure quality primary healthcare for all [1].

SDG 3 calls for health and well-being across all age groups by addressing priority areas such as maternal and child mortality, communicable diseases, non-communicable diseases and mental health, and healthcare workforce. The policy makers worldwide are of considered opinion that without a major shift in the contemporary primary healthcare delivery approach, the base of the pyramid population in developing countries would be left behind in progression towards SDG 3 [2]. To achieve universal health coverage through comprehensive primary healthcare, the potential role of healthcare innovations, especially in resource-constrained environments, has been extensively explored [3].

In developing countries worldwide, there exists a pressing need to address maternal and child healthcare gaps, along with an ever-growing burden of noncommunicable diseases. The existing health disparities-unabated increase in burden of disease among the lowest socioeconomic strata in the poorest countries-are astronomical. New technology holds tremendous potential to mitigate these disparities. In particular, the recent developments in nanotechnology, mobile technology, and information technology may create an enabling environment to foster affordable point-of-care diagnostics for the last-mile populations [4]. The ability of medical technology innovators to successfully deliver new and affordable products in the areas of maximum primary healthcare needs could go a long way in realizing the aim of universal health coverage in countries such as India.

While innovative point-of-care diagnostic devices hold great promise to improve quality of and access to primary healthcare delivery in India, it is imperative to prudently select innovations that have realistic scale-up potential to eventually create a substantial population-level impact. Besides, the unclear regulatory environment with numerous grey areas concerning introduction and commercialization of new innovative point-of-care diagnostic medical devices confounds the situation. This short critique aims to share the evolving regulatory environment and compliance challenges that innovator, nanotechnologists, and public health enthusiasts in India ought to keep in mind before hopping on the bandwagon of innovative point-of-care diagnostic devices in the primary healthcare space. More significantly, the authors, recognizing the public health priorities and the extant regulatory landscape in India, propose a broad approach to inform various stakeholders in the innovation ecosystem on how to identify high-potential innovative point-of-care diagnostic devices whose commercialization of new innovative point-of-care diagnostic medical devices confounds the situation. This short critique aims to share the evolving regulatory environment and compliance challenges that innovator, nanotechnologists, and public health enthusiasts in India ought to keep in mind before hopping on the bandwagon of innovative point-of-care diagnostic devices in the primary healthcare space. More significantly, the authors, recognizing the public health priorities and the extant regulatory landscape in India, propose a broad approach to inform various stakeholders in the innovation ecosystem on how to identify high-potential innovative point-of-care diagnostic devices whose...
lab-based success could be translated into effective and efficient
population-level public health interventions.

THE CURRENT SCENARIO

Point-of-care diagnostic devices are defined as small portable
devices capable of detecting the presence or absence of a disease-
causing agent, a disease, or quantifying the severity or a change in
severity of a disease. Also included in the definition are stand-alone,
one-time use devices that require no additional instrumentation,
minimally-instrumented devices, and devices that include portable
and easy-to-use instrumentation [3].

To address the increasing complexities in the Indian medical
device industry, to enable Indian medical device manufacturers
to enhance the quality of their products and processes, and to
boost the industry’s confidence to try out innovative devices,
Indian certification of medical devices (ICMED), country’s first
indigenously developed international class certification scheme
and quality assurance system for medical devices manufactured
in India, was launched in March 2016 [6]. The ICMED scheme
is an initiative of the Association of Indian Medical Device
Industry (AIMED) in collaboration with the Quality Council
of India (QCI) and the National Accreditation Board for
Certification Bodies (NABCB). The scheme has been launched
with two levels of certification: ICMED 9000 certification,
which is ISO 9001 plus additional requirements, and ICMED
13485, which is ISO 13485 plus additional requirements. The
scheme is expected to improve quality, enhance patient safety,
and eliminate trading of substandard medical devices in the
country. Though the scheme is voluntary, AIMED is strongly
advocating to make it mandatory as ICMED certification would
be able to fill big regulatory vacuum in quality certification space
for medical devices in India.

In 2017, Central Drugs Standard Control Organization (CDSCO)
introduced the Medical Device Rules. The Rules distinguish
medical devices from pharmaceutical products for the purpose of
regulation. Prior to these Rules, notified medical devices in India
were regulated as drugs (pharmaceutical products) under the Drugs
and Cosmetics Act 1940. Unfortunately, since this Act, in which
the definition of ‘drug’ includes all the medical devices, remains
unamended, the Rules under this Act will continue to apply to
all medical devices. However, to avoid confusion, the 2017 Rules
do clarify that in case of any contradiction between the provisions
of 2017 Rules and the Drugs and Cosmetics Rules 1945, the
provisions of the 2017 Rules will have effect [7].

In consonance with the Global Harmonization Task Force (GHTF)
guidelines, the 2017 Rules introduce a risk-based classification
system for regulation of medical devices in India. The classification
would be: low (Class A), low moderate (Class B), moderate
high (Class C), and high risk (Class D). It is important to note
that unlike other countries which give liberty to manufacturers/
importers to classify their product for the purpose of registration,
the 2017 Rules do not provide this liberty and the manufacturers/
importers in India will have to follow the classification decided by
the Drug Controller General of India (DCGI). Broad parameters
for classification of medical devices and in vitro diagnostic
medical devices have been laid down in the first schedule of
the Medical Device Rules 2017 [8]. In addition, inspections by
notified bodies [Quality Management System (QMS) assessments]
have been introduced. The new Rules make it compulsory to
obtain manufacturing and import licenses for all medical devices.
Regarding application for grant of license to the manufacturer,
Class A medical devices do not require prior audit by third party
or official inspection, Class B medical devices require prior audit
by third party but do not require official inspection, and Class
C or Class D medical devices require prior official inspection.
The application for manufacturer of Class A or Class B medical
device will be assessed by the state licensing authority whereas
the application for manufacturer of Class C or Class D medical
device will be assessed by the central licensing authority. The application
for license to import Class A or Class B medical devices from
unregulated jurisdictions can be granted on the strength of a free
sale certificate and of either published safety and performance
data or clinical investigation in the country of origin. However,
an application for import of Class C or Class D medical devices from
unregulated jurisdictions can be granted only after their safety and
effectiveness have been established through clinical investigation in
India. Unregulated jurisdictions are countries other than Australia,
Canada, Japan, European Union countries, or the United States
of America [7].

The 2017 Rules introduce a new regulatory framework for clinical
investigation of medical devices. The Rules have changed the
clinical trial scenario for an investigational medical device from a
four-phase trial like those for drugs to a two-phase trial. The two
phases will be divided into pilot clinical investigation (exploratory
study) and pivotal clinical investigation (confirmatory study). Some
of the other interesting provisions of this framework are:

- a. A fixed timeline of ninety days has been prescribed for the
  licensing authority to arrive at a decision on application for
  permission to conduct clinical trial;
- b. After obtaining permission to conduct clinical trial, the first
  subject is required to be enrolled within one year;
- c. New concept of “substantial equivalence” to predicate devices
  has been introduced with respect to approval of medical devices
  other than investigational medical devices;
- d. The clinical performance evaluation of in vitro diagnostic devices
  is now part of the regulatory framework;
- e. Post-marketing surveillance (PMS) is compulsory after gaining
  marketing approval for the device;
- f. Any institute, organization, or hospital run or funded by the
  Central Government or the State Government is exempted from
  payment of fees for conduct of clinical investigation; and
- g. Academic clinical trials do not require prior approval of the
  licensing authority for its initiation if the data generated during
  the study will not be used for obtaining manufacturing or import
  license.

Form MD22 pertains to grant of permission to conduct clinical
investigation of an investigational medical device and form MD24
concerns grant of permission to conduct clinical performance
evaluation of new in-vitro diagnostic medical device [8]. Besides, all
the processes followed during clinical investigation of any medical
device ought to comply with the New Drugs and Clinical Trials
Rules 2019 [9].

Use of technology readiness level (TRL), originally applied to space
programs, to estimate technology maturation in realms outside
its original context, including in case of innovative diagnostic
medical devices, has been extensively criticized [10]. In this light, introduction of ICMED certification and Medical Device Rules 2017 is a welcome initiative. Additional resources to inform different stakeholders in the medical device innovation space in India include non-regulatory innovation potential utility and novelty (NIPUN) certificate developed by Kalam Institute of Health Technology, proposed medical technology assessment board in the Department of Health Research-Government of India, Draft “National Essential Diagnostics” list developed by Indian Council of Medical Research (ICMR), First WHO Model List of Essential In Vitro Diagnostics, WHO technical series on health technology assessment of medical devices, WHO recommendations on digital interventions for health system strengthening, and Health Technology Accelerated Commercialisation (HTAC) Program initiated by ICMR in collaboration with the Federation of Indian Chambers of Commerce and Industry (FICCI) [11-17].

THE ROAD AHEAD

The Tanahashi framework provides a time-tested model for understanding health system performance gaps and how they prevent the intended coverage, quality, and affordability of health services. The cascading model illustrates how health systems lose performance because of challenges at successive levels, each dependent on the previous level [18]. Health system challenges such as lack of trained human resources for health, unaffordable costs for patients and huge out-of-pocket expenditures, geographical inaccessibility, low demand for services, delayed provision of care, low adherence to clinical protocols, to name a few, contribute to accumulated losses in health system performance. These inadequacies restrict the ability to address the gaps in availability, accessibility, and affordability, and undermine the potential to achieve universal health coverage. Going by the Tanahashi framework, while the availability and contact coverage seem to have improved in India during recent years, this success has not been converted into substantial public health gains, suggesting bottlenecks at different levels of the health system. Notably, health innovations could bolster efforts to address these challenges and achieve universal health coverage.

The insufficient supply and uneven distribution of qualified health professionals severely thwart efforts to achieve the health-related SDGs in developing countries such as India. Understandably, innovative human resources for health approaches are at the heart of the global effort to strengthen health systems and revitalize primary healthcare [19]. Innovative health financing is another tool that can be leveraged to make quality healthcare affordable for all, and thus to drastically decrease out-of-pocket expenditures on healthcare in developing countries [20].

Likewise, innovative point-of-care diagnostic devices can be game changers in making quality healthcare affordable for and accessible to the base of the pyramid population. However, for
these innovations to have substantial population-level benefits, it is imperative to identify innovative point-of-care medical devices that show maximum potential to scale-up into full-fledged public health interventions across the country. Based on the extant regulatory landscape in India, as outlined in this critique, and the current public health priorities, the approach proposed in Figure 1 may assist various stakeholders in the innovation ecosystem to prioritize innovative point-of-care diagnostic devices that hold maximum potential to scale to address the healthcare needs of the last-mile populations across the country.

The Indian public health space represents a unique case of a diverse population with constrained budgets and complex health needs. In this context, the priority-setting approach suggested in this critique needs to be adapted through iterative practice and refinement in order to identify innovative point-of-care diagnostic devices that can eventually raise the quality and cost-effectiveness of healthcare provisions at the last-mile. Instead of merely focusing on technological novelty and sophistication, stakeholders ought to factor in different aspects of the regulatory and public health variables to prioritize affordable, reliable, and cost-effective innovative diagnostic devices for pilot studies and possible scale-ups. Evidence-informed use of innovative point-of-care diagnostics can help improve overall primary healthcare system performance and put India on the trajectory of achieving universal health coverage.

DISCLAIMER

The opinions or views expressed in this article are solely those of the authors and do not necessarily express the views or opinions of the organization to which the authors are affiliated.

ACKNOWLEDGEMENT

This short critique was undertaken as part of the “State Consortium to Accelerate, Leverage, and Economize (SCALE)” initiative. SCALE initiative, implemented as collaboration between Wadhwani Initiative for Sustainable Healthcare (WISH) and USAID, acts as a facilitating platform between the government, private sector organizations, innovators and social enterprises, and healthcare ecosystem partners in bringing together financial and technical resources in catalyzing integration of promising health innovations into the state public health system in India.

REFERENCES

17. http://ficci.in/pressrelease-page.asp?nid=2932
18. World Health Organization. Innov8 approach for reviewing national health programmes to leave no one behind. 2016;p.239.